Cardiotoxicity of Cancer Therapy (CCT)

Enrolling by invitation

Conditions studied: Breast Cancer

In brief

The objective of this study is to define the clinical significance of mechanistic biomarkers (including Neuregulin-1Beta) and novel echocardiographic measures of cardiac function in predicting the incident risk of cancer therapy cardiotoxicity.

Key facts

Study ID

NCT01173341

Run by

Abramson Cancer Center at Penn Medicine

People needed

700

Starts

2010-07-01

Expected to finish

2037-04-01

Last updated by the study team

2026-02-09

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Age 18 years or older
• HER-2 positive breast cancer designated to receive trastuzumab chemotherapy with or without prior exposure to anthracycline-based chemotherapy
• Non-HER-2 positive breast cancer designated to receive treatment with an anthracycline-containing regimen

You may not qualify if…

• Other contraindications to trastuzumab or anthracycline chemotherapy.
• Vulnerable populations

Where it is running

• Abramson Cancer Center of the University of Pennsylvania — Philadelphia, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.